140,113 Shares in Nkarta, Inc. $NKTX Acquired by Nuveen LLC

Nuveen LLC acquired a new position in shares of Nkarta, Inc. (NASDAQ:NKTX) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 140,113 shares of the company’s stock, valued at approximately $258,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Invesco Ltd. boosted its position in shares of Nkarta by 478.4% during the 1st quarter. Invesco Ltd. now owns 69,396 shares of the company’s stock worth $128,000 after purchasing an additional 57,399 shares during the period. Deutsche Bank AG boosted its position in shares of Nkarta by 36.3% during the 1st quarter. Deutsche Bank AG now owns 58,812 shares of the company’s stock worth $108,000 after purchasing an additional 15,655 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Nkarta by 18.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 147,551 shares of the company’s stock worth $271,000 after purchasing an additional 22,538 shares during the period. Monaco Asset Management SAM acquired a new stake in Nkarta during the 1st quarter worth approximately $1,496,000. Finally, CWM LLC lifted its holdings in Nkarta by 3,437.3% during the 1st quarter. CWM LLC now owns 28,157 shares of the company’s stock worth $52,000 after buying an additional 27,361 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NKTX has been the topic of a number of research reports. William Blair reiterated a “market perform” rating on shares of Nkarta in a report on Thursday, May 15th. Wall Street Zen upgraded shares of Nkarta from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Needham & Company LLC reissued a “buy” rating and set a $10.00 target price on shares of Nkarta in a research note on Wednesday, August 13th. Stifel Nicolaus lowered their target price on Nkarta from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Finally, Mizuho lowered their target price on Nkarta from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $13.60.

Nkarta Trading Up 6.1%

Shares of NKTX opened at $2.26 on Friday. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $6.63. The firm’s fifty day simple moving average is $2.05 and its 200-day simple moving average is $1.89. The firm has a market capitalization of $160.53 million, a price-to-earnings ratio of -1.53 and a beta of 0.76.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. On average, analysts predict that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.